ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene

被引：0
|
作者：
Isozaki, Hideko [1 ]
Ichihara, Eiki [1 ]
Yasugi, Masayuki [1 ]
Nobuaki, Ochi [2 ]
Hotta, Katsuyuki [1 ]
Takigawa, Nagio [2 ]
Sendo, Toshiaki [1 ]
Tanimoto, Mitsune [1 ]
Kiura, Katsuyuki [1 ]
机构：
[1] Okayama Univ, Okayama 7008530, Japan
[2] Kawasaki Med Sch, Okayama, Japan
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3721
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EML4-ALK fusion gene in resected non-small-cell lung cancer
    Takahashi, Tsuyoshi
    Sonobe, Makoto
    Menju, Toshi
    Nakayama, Ei
    Mino, Nobuya
    Iwakiri, Shotaro
    Sato, Kiyoshi
    Miyahara, Ryo
    Okubo, Kenichi
    Date, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S483 - S484
  • [32] Clinical effect of crizotinib on lung cancer patients with EML4-ALK fusion gene mutation
    Wang, Zhiyong
    Wang, Wei
    Kong, Xiaodong
    Li, Guangxu
    Yang, Weiwei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11632 - 11638
  • [33] EML4-ALK Variant Affects ALK Resistance Mutations
    Fruh, Martin
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1257 - +
  • [34] Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
    Sugiyama, Keiji
    Izumika, Ai
    Iwakoshi, Akari
    Nishibori, Riko
    Sato, Mariko
    Shiraishi, Kazuhiro
    Hattori, Hiroyoshi
    Nishimura, Rieko
    Kitagawa, Chiyoe
    CURRENT ONCOLOGY, 2021, 28 (03) : 1938 - 1945
  • [35] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
  • [36] Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
    Aydemirli, Mehtap Derya
    van Eendenburg, Jaap D. H.
    van Wezel, Tom
    Oosting, Jan
    Corver, Willem E.
    Kapiteijn, Ellen
    Morreau, Hans
    ENDOCRINE-RELATED CANCER, 2021, 28 (06) : 377 - 389
  • [37] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [38] Mechanisms of Alectinib Resistance in a Leptomeningeal Carcinomatosis of EML4-ALK Lung Cancer and Its Circumvention by EGR-TKIs
    Yano, S.
    Arai, S.
    Fukuda, K.
    Takeuchi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S29 - S29
  • [39] Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma
    Jiang, Liqun
    Chen, Suping
    Stinnett, Victoria
    Haley, Lisa
    Morsberger, Laura
    Shane, Alison
    Hardy, Melanie
    Smith, Kirstin
    Gocke, Christopher D.
    Lin, Ming-Tseh
    Zhou, Ying S.
    CANCER GENETICS, 2021, 258 : 18 - 22
  • [40] Clinicopathological features of younger (aged 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene
    Kometani, Takuro
    Sugio, Kenji
    Osoegawa, Atsushi
    Seto, Takashi
    Ichinose, Yukito
    THORACIC CANCER, 2018, 9 (05) : 563 - 570
12345